Metaglip
Formulated to manage type 2 diabetes mellitus, this combined therapy is utilized to support blood glucose control and to mitigate glycemic fluctuations.
Strengths: 2.5/500 · 5/500mg
Where to Check Availability
Medicine details
- Conditions
- Alternative names
Glucovance
- Therapeutic class
Biguanide; Sulfonylurea
- Pharmacological class
Biguanide; Sulfonylurea
- Precautions and warnings
monitor blood glucose levels; risk of lactic acidosis; monitor for hypoglycaemia
- Minor side effects
nausea; diarrhoea; abdominal discomfort
- Moderate side effects
hypoglycaemia; dizziness; weight gain
- Dosage forms
Tablet
- Administration route
Oral use
- Prescription status
POM
- Manufacturer
Bristol-Myers Squibb
- Onset Time
1–2 hours
- Duration
12–24 hours
- Storage instructions
Store at room temperature.
- Drug interactions
alcohol; cimetidine; diuretics; corticosteroids
- Age restrictions
Not for use in children.
- Pregnancy and breastfeeding
Pregnancy: Insulin is preferred. Breastfeeding: Not recommended.
Contraindications
type 1 diabetes; diabetic ketoacidosis; severe renal impairment; severe hepatic impairment
Serious side effects
lactic acidosis — requires immediate medical attention; anaphylaxis — requires immediate medical attention
Patient summary
Formulated to manage type 2 diabetes mellitus, this combined therapy is utilized to support blood glucose control and to mitigate glycemic fluctuations.
Mechanism of action
Metformin reduces hepatic glucose production and increases insulin sensitivity, while glipizide stimulates pancreatic insulin secretion, providing a dual approach to glycemic management.
Metaglip
Formulated to manage type 2 diabetes mellitus, this combined therapy is utilized to support blood glucose control and to mitigate glycemic fluctuations.
Editorial Notes
- Active ingredient(s): Glipizide, Metformin
- Listed indication(s): Type 2 Diabetes Mellitus